Nerandomilast is a medication taken by mouth in tablet form. It is being studied to see if it can help reduce the risk of lung abnormalities or scarring getting worse in people who have a family history of pulmonary fibrosis.

Interstitial lung diseases – These are a group of disorders that cause inflammation and scarring in the lungs. The condition occurs when the tissue around the air sacs becomes thickened and stiff. As the disease progresses, the lung tissue loses its elasticity, making it harder for the lungs to expand. This thickening can interfere with the efficient exchange of oxygen and carbon dioxide. The progression varies depending on the specific type of interstitial disease involved.

Familial pulmonary fibrosis – This is a rare form of lung disease characterized by the scarring of lung tissue that is passed down through families due to genetic factors. The condition leads to the buildup of thick, fibrous tissue within the lungs. Over time, this scarring makes the lung tissue stiff and less functional. The disease typically progresses as the lung architecture becomes increasingly distorted by the fibrosis.

Pulmonary fibrosis – This condition involves the progressive scarring and thickening of the lung tissue. As the scarring increases, the lungs become stiff and lose their ability to expand easily. This process makes it difficult for the lungs to transfer oxygen into the bloodstream. The disease moves forward as the fibrous tissue continues to accumulate throughout the lungs.